Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusDevelopment of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genesPotential Antiviral Agents from Marine Fungi: An OverviewUnity in diversity: shared mechanism of entry among paramyxovirusesCX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent MannerPhylodynamics and dispersal of HRSV entails its permanence in the general population in between yearly outbreaks in childrenAdaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivoStructural basis of viral invasion: lessons from paramyxovirus FHerpes Simplex Virus Type 2 Glycoprotein G Is Targeted by the Sulfated Oligo- and Polysaccharide Inhibitors of Virus Attachment to CellsRespiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial CulturesEGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin ExpressionRespiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2.Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy.Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus.Respiratory syncytial virus infection in adultsHighly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantThe respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodentsAnimal pneumoviruses: molecular genetics and pathogenesis.The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.Structure and function of respiratory syncytial virus surface glycoproteins.Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Infectivity of a human respiratory syncytial virus lacking the SH, G, and F proteins is efficiently mediated by the vesicular stomatitis virus G protein.Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.Nucleotide and predicted amino acid sequence-based analysis of the avian metapneumovirus type C cell attachment glycoprotein gene: phylogenetic analysis and molecular epidemiology of U.S. pneumoviruses.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsIdentification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractEffect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection.Functional Analysis of the 60-Nucleotide Duplication in the Respiratory Syncytial Virus Buenos Aires Strain Attachment Glycoprotein.Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeuticsCX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein.Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimersHeparin octasaccharide decoy liposomes inhibit replication of multiple virusesThe host response and molecular pathogenesis associated with respiratory syncytial virus infection.
P2860
Q26748856-2A75C0D4-DAFC-4903-A73B-EA06B5D91AC9Q26782411-FC7D4E0C-0B24-4728-8F46-ACBD0DB4EAFFQ26800107-52EF3DCD-401F-4990-A720-E8222293F4A0Q26864825-ADB81532-2D57-4988-98AC-FFB5578643F6Q27303940-9618122F-2544-4DDE-BDC4-98AEEDF3B1C5Q27329785-82329CBB-B44D-4041-B4FA-7975A5106367Q27469802-266CB774-AB6B-4A10-8A6A-98AE222CC79DQ27481675-340BAED7-F95D-4DB2-BBB3-B0142848A689Q27485008-64903A64-3204-4CF7-9BB3-F3A935133050Q28551477-3D788F03-947D-4E27-8FAA-D4108CDB309FQ28551865-94CF85E8-F119-4E41-98FF-23FFD6E8CB52Q30425776-6BAB493B-DCBE-4B69-9F10-2488B7A97C9CQ33263085-8BE04F0E-2973-4B53-A1BF-F65E93ACCC58Q33787265-077CAAB3-1F36-4ACF-AB54-B54B009AE0AEQ33842098-1F8D3EFD-1089-4369-B06F-324367AB57DEQ33961877-4D547F77-00D9-4C05-B44B-8BB349560903Q34057989-7185E383-B9EC-4B13-9734-F01856C9D8EDQ34151000-72CB55FB-5748-4518-AE8E-CE95FE02E309Q34151865-50EDBDAE-EA78-4E84-89B7-1C206D3489A4Q34182385-9A2C3BA4-A415-4590-A890-187EE8F0383AQ34222406-665F8388-BC99-4050-BC4C-7709F1D5099DQ34313560-0BB94A2C-9368-4CED-9488-CF31787D75C4Q34340452-0D28F6A5-74F7-418E-AC92-C49B5C61D265Q34414405-CB099B95-7EEC-46C4-B987-266C0FE2EE84Q34466061-4A64C331-9537-427F-BE34-B6BF682E0C9BQ34504791-D67A73D9-02A5-4BD7-B703-6BD0272F3CD7Q34744464-9AC9505B-48A7-47F2-A7FA-9C35AFBE5F95Q34825946-8CC632A3-C188-488A-A60D-6DA64BCBE547Q34974594-021EA0EA-E257-41EC-862A-E1E970B50D2FQ35566601-28B3D598-E7E3-4574-A0E5-47BCEEB19CE8Q35634327-A5FB4E12-090E-4E0B-BCCE-AA3E38B622C0Q35690781-4EE65A07-3CC5-4BDB-949D-4FBC5B9FCBF9Q35747504-EBC081CA-60B1-4260-A060-1E6EBB22F56BQ35914372-A69462CE-B968-4408-ADA5-6BD1B169D46CQ36174346-6C5BA856-C12F-4F59-B8E7-EB13B3061913Q36255118-94ED0208-4690-46F6-B786-D55FC255B393Q36433969-11888437-9064-43A7-B862-EA636DA654A8Q36879938-399118BF-3AE6-438E-9718-B535CAAB224CQ37182445-CD0C6BAC-3D13-47C7-9D99-0EDD21EA90D3Q37263779-257CBD5D-6223-4BE3-88D7-AFED8A0BA1A7
P2860
Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Identification of a linear hep ...... rus attachment glycoprotein G.
@en
Identification of a linear hep ...... rus attachment glycoprotein G.
@nl
type
label
Identification of a linear hep ...... rus attachment glycoprotein G.
@en
Identification of a linear hep ...... rus attachment glycoprotein G.
@nl
prefLabel
Identification of a linear hep ...... rus attachment glycoprotein G.
@en
Identification of a linear hep ...... rus attachment glycoprotein G.
@nl
P2093
P2860
P1433
P1476
Identification of a linear hep ...... rus attachment glycoprotein G.
@en
P2093
J A Beeler
R M Hendry
S A Feldman
P2860
P304
P407
P577
1999-08-01T00:00:00Z